{"schema_version":"secwatch.filing_event.v1","accession":"0001785530-22-000012","form_type":"8-K","ticker":"HOWL","cik":"0001785530","company_name":"Werewolf Therapeutics, Inc.","filed_at":"2022-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.201028+00:00","generated_at":"2026-06-26T18:41:12.584740+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Werewolf Therapeutics reports 2021 net loss $50M, cash $157.5M; IND filings on track","bullets":["Net loss $17.9M in Q4 2021 ($7.4M Q4 2020); full-year loss $50.0M ($15.0M 2020).","Cash $157.5M at Dec 31, 2021 ($92.6M Dec 31, 2020); runway through at least Q2 2023.","R&D expenses $35.3M in 2021 ($16.6M 2020); G&A $14.8M ($5.8M).","IND for WTX-124 expected Q2 2022; IND for WTX-330 early Q3 2022.","Announced clinical trial collaboration with Merck for WTX-124 + Keytruda in solid tumors."],"urls":{"canonical":"https://secwatch.observer/filing/0001785530-22-000012","json":"https://secwatch.observer/filing/0001785530-22-000012.json","markdown":"https://secwatch.observer/filing/0001785530-22-000012.md","text":"https://secwatch.observer/filing/0001785530-22-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785530/000178553022000012/0001785530-22-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785530/000178553022000012/howl-20220324.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T18:41:12.584740+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}